“We can deliver very promptly, hopefully from the beginning of September,” company boss Ugur Sahin told the “Spiegel”. The EMA recently announced that the responsible committee will decide on the applications from BioNTech/Pfizer and the US company Moderna for approval of their vaccines adapted to the BA.1 subtype on September 1st.
In Germany, this variant no longer plays a role. The hope is that this vaccine will also work better against the currently circulating variants.
The EMA is also currently testing a corona vaccine from the Mainz-based company and its US partner Pfizer that has been adapted to the current Omicron variants BA.4 and BA.5. BioNTech is currently submitting the last documents to the EMA, Sahin told the “Spiegel”: “Then things can go quickly here too.”
In NASDAQ trading, the BioNTech share temporarily rose by 0.95 percent to $147.63. Pfizer shares are down 0.08 percent on the NYSE at $47.39.
/mba/DP/mis
MAINZ (dpa-AFX)
Leverage must be between 2 and 20
No data
More news about BioNTech (ADRs)
Image sources: Marco Lazzarini / Shutterstock.com, Pavlo Gonchar/SOPA Images/LightRocket via Getty Images